**Core Concept**
The management of carcinoma breast involves a multidisciplinary approach, including surgery, chemotherapy, radiation therapy, and hormone therapy. Hormone therapy, specifically targeted therapy, plays a crucial role in the treatment of hormone receptor-positive breast cancer.

**Why the Correct Answer is Right**
Trastuzumab, a monoclonal antibody, is widely used in the management of HER2-positive breast cancer. It targets the HER2/neu receptor, a protein that promotes the growth of cancer cells. By binding to this receptor, trastuzumab inhibits the proliferation of cancer cells and induces apoptosis. This targeted therapy has significantly improved the survival rates of patients with HER2-positive breast cancer.

**Why Each Wrong Option is Incorrect**
**Option A:** Tamoxifen is a selective estrogen receptor modulator (SERM) used in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. However, it is not the correct answer in this context.
**Option B:** Letrozole is an aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. While it is effective in reducing estrogen levels, it is not the correct answer in this context.
**Option C:** Capecitabine is an oral chemotherapy medication used in the treatment of metastatic breast cancer. While it is used in the management of breast cancer, it is not the correct answer in this context.

**Clinical Pearl / High-Yield Fact**
Trastuzumab is often used in combination with other therapies, such as chemotherapy and radiation therapy, to improve treatment outcomes in HER2-positive breast cancer. The use of trastuzumab has significantly improved the survival rates of patients with this type of breast cancer.

**Correct Answer:** C.